Back to search results

Study of DCC-2812 for Advanced Genitourinary Cancers

This study is testing a drug called DCC-2812 for people with advanced or metastatic (spread to other parts of the body) renal cell carcinoma (kidney cancer), urothelial carcinoma (bladder cancer), or castration-resistant prostate cancer. DCC-2812 is taken by mouth. The main goal is to see how safe DCC-2812 is, by tracking side effects and how many people need to stop or reduce their dose because of them. Researchers also want to see if it shows any early signs of helping with these cancers. You may be able to join if you are 18 or older, can take oral medication, and have one of these confirmed cancers. The study is currently unclear on its recruitment status and plans to enroll about 60 participants.

Study design
This is a multicenter clinical trial to evaluate the safety and preliminary activity of DCC-2812 as a single treatment. The study plans to enroll about 60 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Researchers will track side effects and dose changes for up to 42 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06966024

Study of DCC-2812 in Participants With Advanced Genitourinary Cancers

Recruiting
PHASE1Ages 18+InterventionalTreatment
Deciphera Pharmaceuticals, LLC
~60 participants
Updated 2026-08-18 on ClinicalTrials.gov
What's tested:DCC-2812

At a glance

Recruiting sites
8 of 8 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of Participants with Dose-limiting Toxicities (DLTs)
Measured over Cycle 1 (28 days)
+2 more outcomes measured

Conditions

Renal Cell Carcinoma
Urothelial Carcinoma
Castration-resistant Prostate Cancer

Explore related trials

Prostate CarcinomaRenal Cell CarcinomaSolid NeoplasmUrothelial Carcinoma

Where it's being run

8 sites across 7 states
Texas2
Massachusetts1
Michigan1
Missouri1
Ohio1
Pennsylvania1
Tennessee1

Study leadership

  • Clinical Team · STUDY_DIRECTOR · Deciphera Pharmaceuticals, LLC

Who to contact

Clinical Team
[email protected]
888-724-3274
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Have confirmed Advanced or Metastatic Renal Cell Carcinoma, Urothelial Cancer, or Castration-Resistant Prostate Cancer
Able to take oral medication
If a female is of childbearing potential, must have a negative pregnancy test prior to enrollment and all participants agree to follow the contraception requirements
Adequate organ function and electrolytes

Exclusion

Received any prior anticancer therapy or any investigational therapy within a specified timeframe prior to first dose of DCC-2812
Impaired cardiac function
Major surgery within 28 days of the first dose of study drug

What this trial measures

  • Number of Participants with Dose-limiting Toxicities (DLTs)Cycle 1 (28 days)
  • Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Up to 42 months
  • Number of Participants With Dose Reduction, Interruption, or Discontinuation of Study Drug Due to TEAEsUp to 42 months